Drew Deniger
Equibles does not estimate personal net worth.
About Drew Deniger
Alaunos Therapeutics, Inc. reported in an 8-K filed November 15, 2023 that Drew Deniger was terminated as Vice President, Research and Development, effective November 15, 2023. The proxy statement of Alaunos Therapeutics, Inc. reports total compensation of $629,680 for Drew Deniger in fiscal 2023, including a base salary of $317,757. Disclosed compensation is on record for 2 fiscal years.
“on November 10, 2023, Alaunos Therapeutics, Inc. (the "Company") terminated the employment of Melinda Lackey, Senior Vice President, Legal and Administration, and Drew Deniger, Vice President, Research and Development, "Without Cause" (as defined in their respective employment agreements) and, per their respective retention agreements, not because either failed to perform their duties at an "Acceptable Level" (as defined therein), effective November 15, 2023.”
Affiliation history
-
Alaunos Therapeutics, Inc. (TCRT)
Proxy statement
Start not stated–2023-11-15
Company network
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | Alaunos Therapeutics, Inc. (TCRT) | VP, Research and Development | $317,757 | $629,680 |
| 2022 | Alaunos Therapeutics, Inc. (TCRT) | VP, Research and Development | $345,572 | $949,113 |